Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05852938




Registration number
NCT05852938
Ethics application status
Date submitted
2/05/2023
Date registered
10/05/2023
Date last updated
28/10/2024

Titles & IDs
Public title
A Study of BION-1301 in Adults With IgA Nephropathy
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
Secondary ID [1] 0 0
CHK02-02
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
IgA Nephropathy 0 0
Immunoglobulin A Nephropathy 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BION-1301
Treatment: Drugs - Placebo

Experimental: BION-1301 - 600mg subcutaneous administration every 2 weeks for 104 weeks

Placebo comparator: Placebo - subcutaneous administration every 2 weeks for 104 weeks


Treatment: Drugs: BION-1301
BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.

Treatment: Drugs: Placebo
Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in proteinuria (natural log UPCR)
Timepoint [1] 0 0
40 weeks or approximately 9 months
Secondary outcome [1] 0 0
Change in eGFR
Timepoint [1] 0 0
104 weeks or approximately 2 years
Secondary outcome [2] 0 0
Effect of BION-1301 on specific clinical composite endpoints (30% eGFR reduction)
Timepoint [2] 0 0
Baseline and Weeks 4, 12, 24, 40, 52, 64, 76, 88, and 104
Secondary outcome [3] 0 0
Effect of BION-1301 on specific clinical composite endpoints (40% eGFR reduction)
Timepoint [3] 0 0
Baseline and Weeks 4, 12, 24, 40, 52, 64, 76, 88, and 104
Secondary outcome [4] 0 0
Percent Change in Proteinuria and Total Urine Protein
Timepoint [4] 0 0
40 weeks or approximately 9 months

Eligibility
Key inclusion criteria
* Male and female participants aged = 18 years at the time of signing the informed consent form (ICF) prior to initiation of any study specific activities/procedures.
* Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. A pseudonymized copy of the report must be available for review by the Sponsor or designee prior to randomization. If biopsy report within 10 years is not available, re-biopsy may be permitted upon discussion with the Medical Monitor.
* eGFR = 30 mL/min/1.73m^2 at Screening based on the 2021 CKD-EPI equation.
* Total urine protein = 1.0 g/day and UPCR = 0.7 g/g (700 mg/g), as measured from an adequate 24-hour urine collection at Screening by a central laboratory.
* Stable on a maximally tolerated dose of ACEi/ARB for at least 12 weeks prior to Screening unless intolerant to ACEi/ARB. May also be on a stable and well tolerated dose of SGLT2i and/or ERAs/MRAs for at least 12 weeks prior to Screening for the treatment of IgAN. Participants are expected to stay on the ACEi/ARB, SGLT2i and/or the ERAs/MRAs for the duration of the study.
* Body mass index (BMI) between 18 and 40 kg/m^2.
* Screening weight of 45 to 150 kg.
* Men and women of childbearing potential (WOCBP; per Clinical Trials Facilitation and Coordination Group [CTFG] 2020) must agree to follow protocol-specified contraception guidance from Screening through approximately 5 half-lives (24 weeks) after the final dose of study drug. Use of hormonal contraceptive agents must have been initiated > 1 month prior to first dose of study drug.
* Provide written informed consent and be willing to comply with study visits and procedures.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, autoimmune disorders or neoplasias.
* Diagnosis of IgA Vasculitis.
* Current or history of nephrotic syndrome.
* Average blood pressure > 150/90 mm Hg (systolic/diastolic) from 3 readings obtained at the initial Screening visit. If blood pressure is too high, the 3 readings may be repeated once within the Screening period if clinically appropriate as per the Investigator.
* Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on KDIGO guidelines
* Chronic Kidney Disease, either clinically suspected or based on biopsy, resulting from any condition or another glomerulopathy/podocytopathy other than IgAN.
* History of Type 1 Diabetes.
* Participants with Type 2 diabetes are excluded if any of the following are present:

* Screening HbA1c (glycated hemoglobin) of > 8%.
* Evidence of diabetic changes on kidney biopsy, performed for any reason.
* History of diabetic microvascular disease (retinopathy, neuropathy, nephropathy) and/or macrovascular disease (atherosclerotic heart disease, peripheral vascular disease, cerebrovascular disease).
* Unstable anti-diabetic regimen:
* Prior exposure to any antibody directed against APRIL.
* History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis, including a history of allergy or hypersensitivity to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody.
* Received an investigational new drug within 28 days or 5 half-lives, whichever is longer, prior to Screening.
* Received systemic corticosteroid therapy including budesonide (Tarpeyo/Kinpeygo) for > 14 days within 12 weeks prior to Screening.
* Use of systemic immunosuppressant medications.
* Any confirmed or suspected immunosuppressive or immune-deficient state, including but not limited to common variable immunodeficiency (CVID), HIV infection or asplenia, history of bone marrow or organ transplantation with exception of corneal transplants.
* Current severe infection requiring antimicrobials or history of recurrent, severe, infections as determined by the Investigator.
* Positive serology test for hepatitis A virus IgM antibodies (anti-HAV IgM), hepatitis B surface antigen (HBsAg), detectable hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) antibodies (participants who completed treatment and are persistently antibody be allowed), or antibodies to HIV-1 and/or HIV-2 at Screening.
* Received a live vaccination within 12 weeks prior to Screening or plan to have a live vaccination within 6 months after the last dose of study drug.
* History of malignancy unless cancer free for at least 5 years or non-melanoma skin cancer that was completely resected. A participant with curatively treated cervical carcinoma in situ is eligible for the study. Participants with low-risk prostate cancer (i.e., Gleason score < 7 and prostate specific antigen < 10 ng/mL) are allowed.
* Pregnancy or breastfeeding or intent to become pregnant or to donate sperm during the study period and until 24 weeks after last dose.
* History or evidence of any other clinically significant disorder, condition, disease, or laboratory finding that, in the Investigator's assessment, would place the participant at unacceptable risk, limit compliance with study requirements, or confound interpretation of study results.
* IgG levels < 6 g/L at Screening.
* Participation in another interventional trial with an investigational agent/device is prohibited during the course of this study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/07/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
7/06/2028
Actual
Sample size
Target
292
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Gosford
Recruitment hospital [2] 0 0
Novartis Investigative Site - Kogarah
Recruitment hospital [3] 0 0
Novartis Investigative Site - Liverpool
Recruitment hospital [4] 0 0
Novartis Investigative Site - Penrith
Recruitment hospital [5] 0 0
Novartis Investigative Site - Cairns North
Recruitment hospital [6] 0 0
Novartis Investigative Site - Box Hill
Recruitment hospital [7] 0 0
Novartis Investigative Site - St Albans
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2170 - Liverpool
Recruitment postcode(s) [4] 0 0
2750 - Penrith
Recruitment postcode(s) [5] 0 0
4870 - Cairns North
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
3021 - St Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Catamarca
Country [20] 0 0
Argentina
State/province [20] 0 0
Ciudad Autónoma De BuenosAires
Country [21] 0 0
Argentina
State/province [21] 0 0
Santa Fe
Country [22] 0 0
Argentina
State/province [22] 0 0
Ciudad Autónoma de Buenos Aires
Country [23] 0 0
Belgium
State/province [23] 0 0
Antwerpen
Country [24] 0 0
Belgium
State/province [24] 0 0
Oost-Vlaanderen
Country [25] 0 0
Belgium
State/province [25] 0 0
West-Vlaanderen
Country [26] 0 0
Belgium
State/province [26] 0 0
Liège
Country [27] 0 0
Belgium
State/province [27] 0 0
Lodelinsart
Country [28] 0 0
Belgium
State/province [28] 0 0
Woluwe-Saint-Lambert
Country [29] 0 0
Brazil
State/province [29] 0 0
Amapá
Country [30] 0 0
Brazil
State/province [30] 0 0
Minas Gerais
Country [31] 0 0
Brazil
State/province [31] 0 0
Rio Grande Do Sul
Country [32] 0 0
Brazil
State/province [32] 0 0
Santa Catarina
Country [33] 0 0
Brazil
State/province [33] 0 0
São Paulo
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
China
State/province [35] 0 0
Guangdong
Country [36] 0 0
Croatia
State/province [36] 0 0
Grad Zagreb
Country [37] 0 0
Croatia
State/province [37] 0 0
Biškupec Zelinski
Country [38] 0 0
Croatia
State/province [38] 0 0
Rijeka
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha, Hlavní Mesto
Country [40] 0 0
France
State/province [40] 0 0
Gard
Country [41] 0 0
France
State/province [41] 0 0
Nord
Country [42] 0 0
France
State/province [42] 0 0
Rhône
Country [43] 0 0
France
State/province [43] 0 0
Grenoble
Country [44] 0 0
France
State/province [44] 0 0
Paris
Country [45] 0 0
Germany
State/province [45] 0 0
Niedersachsen
Country [46] 0 0
Germany
State/province [46] 0 0
Rheinland-Pfalz
Country [47] 0 0
Germany
State/province [47] 0 0
Sachsen-Anhalt
Country [48] 0 0
Germany
State/province [48] 0 0
Thüringen
Country [49] 0 0
Germany
State/province [49] 0 0
Essen
Country [50] 0 0
Greece
State/province [50] 0 0
Achaïa
Country [51] 0 0
Greece
State/province [51] 0 0
Attiki
Country [52] 0 0
Greece
State/province [52] 0 0
Thessaloniki
Country [53] 0 0
Greece
State/province [53] 0 0
Heralkion
Country [54] 0 0
Greece
State/province [54] 0 0
Ioannina
Country [55] 0 0
India
State/province [55] 0 0
Andhra Pradesh
Country [56] 0 0
India
State/province [56] 0 0
Rajasthan
Country [57] 0 0
India
State/province [57] 0 0
Uttar Pradesh
Country [58] 0 0
India
State/province [58] 0 0
Dehradun
Country [59] 0 0
Israel
State/province [59] 0 0
HaDarom
Country [60] 0 0
Israel
State/province [60] 0 0
Tel-Aviv
Country [61] 0 0
Israel
State/province [61] 0 0
Be'er Ya'akov
Country [62] 0 0
Israel
State/province [62] 0 0
Ramat Gan
Country [63] 0 0
Italy
State/province [63] 0 0
Friuli-Venezia Giulia
Country [64] 0 0
Italy
State/province [64] 0 0
Lazio
Country [65] 0 0
Italy
State/province [65] 0 0
Lombardia
Country [66] 0 0
Japan
State/province [66] 0 0
Aiti
Country [67] 0 0
Japan
State/province [67] 0 0
Hokkaidô
Country [68] 0 0
Japan
State/province [68] 0 0
Hukuoka
Country [69] 0 0
Japan
State/province [69] 0 0
Kanagawa
Country [70] 0 0
Japan
State/province [70] 0 0
Nara
Country [71] 0 0
Japan
State/province [71] 0 0
Tiba
Country [72] 0 0
Japan
State/province [72] 0 0
Tokyo
Country [73] 0 0
Japan
State/province [73] 0 0
Chiba
Country [74] 0 0
Japan
State/province [74] 0 0
Niigata
Country [75] 0 0
Japan
State/province [75] 0 0
Okayama
Country [76] 0 0
Japan
State/province [76] 0 0
Ôita
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Gyeonggido
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Seoul Teugbyeolsi
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Cheonan
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Daejeon
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Malaysia
State/province [82] 0 0
Pahang
Country [83] 0 0
Malaysia
State/province [83] 0 0
Sarawak
Country [84] 0 0
Malaysia
State/province [84] 0 0
Selangor
Country [85] 0 0
Malaysia
State/province [85] 0 0
WilayahPersekutuan KualaLumpur
Country [86] 0 0
Mexico
State/province [86] 0 0
Chiapas
Country [87] 0 0
Mexico
State/province [87] 0 0
Distrito Federal
Country [88] 0 0
Mexico
State/province [88] 0 0
Aguascalientes
Country [89] 0 0
Mexico
State/province [89] 0 0
Chihuahua
Country [90] 0 0
Mexico
State/province [90] 0 0
Monterrey
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona
Country [92] 0 0
Spain
State/province [92] 0 0
Girona
Country [93] 0 0
Spain
State/province [93] 0 0
Lleida
Country [94] 0 0
Spain
State/province [94] 0 0
Lugo
Country [95] 0 0
Spain
State/province [95] 0 0
Madrid
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Taiwan
State/province [97] 0 0
Changhua County
Country [98] 0 0
Taiwan
State/province [98] 0 0
Hsinchu City
Country [99] 0 0
Taiwan
State/province [99] 0 0
Hualien City
Country [100] 0 0
Taiwan
State/province [100] 0 0
Kaohsiung
Country [101] 0 0
Taiwan
State/province [101] 0 0
Keelung
Country [102] 0 0
Taiwan
State/province [102] 0 0
Tainan
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taipei City
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taipei city
Country [105] 0 0
Turkey
State/province [105] 0 0
Izmir
Country [106] 0 0
Turkey
State/province [106] 0 0
Kocaeli
Country [107] 0 0
Turkey
State/province [107] 0 0
Antalya
Country [108] 0 0
Turkey
State/province [108] 0 0
Kayseri
Country [109] 0 0
United Kingdom
State/province [109] 0 0
East Sussex
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Lancashire
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Bristol
Country [112] 0 0
United Kingdom
State/province [112] 0 0
London
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Chinook Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Trial website
https://clinicaltrials.gov/study/NCT05852938
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05852938